Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain

Pain Medicine (United States)

Volumn 14, Issue 11, 2013, Pages 1631-1649

  Kumar, Krishna ^a   Rizvi, Syed ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Chronic Pain; Conventional Medical Management; Cost Comparison; Cost Effectiveness; Spinal Cord Stimulation

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE;

ADULT; AGED; ALTERNATIVE MEDICINE; ANALGESIA; ANGINA PECTORIS; ARTICLE; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVALUATION AND FOLLOW UP; FAILED BACK SURGERY SYNDROME; FEMALE; HEALTH CARE PERSONNEL; HEALTH STATUS; HOSPITAL SERVICE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; IMAGING; IMPLANTABLE PULSE GENERATOR; IMPLANTATION; INCREMENTAL COST EFFECTIVENESS RATIO; INCREMENTAL NET MONETARY BENEFIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY ADJUSTED LIFE YEAR; REFRACTORY ANGINA PECTORIS; SENSITIVITY ANALYSIS; SPINAL CORD STIMULATION; THERAPY EFFECT; TRANSCUTANEOUS NERVE STIMULATION; VISUAL ANALOG SCALE;

CHRONIC PAIN; CONVENTIONAL MEDICAL MANAGEMENT; COST COMPARISON; COST-EFFECTIVENESS; SPINAL CORD STIMULATION;

ANGINA PECTORIS; CANADA; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROMES; COST-BENEFIT ANALYSIS; FAILED BACK SURGERY SYNDROME; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; QUALITY-ADJUSTED LIFE YEARS; SPINAL CORD STIMULATION;

EID: 84887824125     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12146     Document Type: Article

References (52)

1. Kumar Taylor RS, Jacques L, Eldabe S, etal. Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain 2007;132(1-2):179-188.
2. Kumar K, Taylor RS, Jacques L, etal. The effects of spinal cord stimulation in neuropathic pain are sustained: A 24-month follow-up of the PROCESS trial. Neurosurgery 2008;63:762-770.
3. North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: A randomized, controlled trial. Neurosurgery 2005;56:98-107.
4. Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment of chronic benign pain: Challenges in treatment planning and present status, a 22-year experience. Neurosurgery 2006;58:481-496.
5. Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van Kleef M. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: Five-year final follow-up of patients in a randomized controlled trial. J Neurosurg 2008;108:292-298.
6. Kumar K, Rizvi S, Bishop S. Spinal cord stimulation is effective in management of complex regional pain syndrome (CRPS) I: Fact or Fiction. Neurosurgery 2011;69(3):566-580.
7. Harke H, Gretenkort P, Ladleif HU, Rahman S. Spinal cord stimulation in sympathetically maintained complex regional pain syndrome type I with severe disability A prospective clinical study. Eur J Pain 2005;9(4):363-373.
8. Ekre O, Eliasson T, Norrsell H, Währborg P, Mannheimer C. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J 2002;23:1938-1945.
9. Andrèll P, Yu W, Gersbach P, etal. Long-term effects of spinal cord stimulation on angina symptoms and quality of life in patients with refractory angina pectoris results from the European Angina Registry Link Study (EARL). Heart 2010;96:1132-1136.
10. Amann W, Berg P, Gersbach P, Gamain J, Rápale JH. Ubbicnk D for the SCS-EPOS study group. Spinal cord stimulation in the treatment of non-reconstructable stable critical leg ischaemia: Result of the European peripheral vascular disease outcome study (SCS-EPOS). Eur J Vasc Endovasc Surg 2003;26:280-286.
11. Kumar K, Toth C, Nath KR, Verma AK, Burgess JJ. Improvement of limb circulation in peripheral vascular disease using epidural spinal cord stimulation: A prospective study. J Neurosurg 1997;6:662-669.
12. Cruccu G, Aziz TZ, Garcia-Larrea L, etal. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007;14(9):952-970.
13. Kemler M, Furnee C. Economic evaluation of spinal cord stimulation for chronic reflex sympathetic dystrophy. Neurology 2002;59:1203-1209.
14. Kemler MA, Raphael JH, Bentley A, Taylor RS. The cost-effectiveness of spinal cord stimulation for complex regional pain syndrome. Value Health 2010;13(6):735-742.
15. Kumar K, Malik S, Demeria D. Treatment of chronic pain with spinal cord stimulation versus alternative therapies: Cost-effectiveness analysis. Neurosurgery 2002;51(1):106-116.
16. North RB, Kidd DH, Shipley J, Taylor RS. Spinal cord stimulation versus reoperation for failed back surgery syndrome: A cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery 2007;61:361-369.
17. Taylor RS, Ryan J, O'Donnell R, etal. The cost-effectiveness of spinal cord stimulation in the treatment of failed back surgery syndrome. Clin J Pain 2010;26:463-469.
18. Andrell P, Ekre O, Eliasson T, etal. Cost-effectiveness of spinal cord stimulation versus coronary artery bypass grafting in patients with severe angina pectoris-long-term results from the ESBY study. Cardiology 2003;99:20-24.
19. Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann P. Cost-utility analysis studies of depression management: A systematic review. Am J Psychiatry 2004;161:2155-2162.
20. Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996;34(12):DS197-DS199.
21. Gold MR, Patrick DL, Torrance GW, etal. Identifying and valuing outcomes. In: Gold ME, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:82-134.
22. Thoma A, Strumas N, Rockwell G, McKnight L. The Use of Cost-Effectiveness Analysis in Plastic Surgery Clinical Research. Clin Plast Surg 2008;35:285-296.
23. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. (Panel on Cost-Effectiveness in Health and Medicine). The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177.
24. Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edition. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2006:Available at: www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf (accessed May 6 2012).
25. Simpson EL, Duenas A, Holmes MW, Papaioannou D, Chilcott J. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: Systematic review and economic evaluation. Health Technol Assess 2009;13:iii, ix-iix, 1-154.
26. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2008.
27. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation. Med Decis Making 2005;25(6):667-677.
28. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008;46(4):343-345.
29. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13(5):437-452.
30. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-884.
31. Wee HL, Machin D, Loke WC, etal. Assessing differences in utility scores: A comparison of four widely used preference-based instruments. Value Health 2007;10:256-265.
32. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-1189.
33. Briggs A, Claxton K, Schulpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
34. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415-430.
35. Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886-897.
36. Ringuest JL. Lp-metric sensitivity analysis for single and multi-attribute decision-analysis. Eur J Oper Res 1997;98:563-570.
37. Smith CL, Borgonovo E. Decision making during nuclear power plant incidents-a new approach to the evaluation of precursor events. Risk Anal 2007;27:1027-1042.
38. Medtronic. RestoreAdvanced Multi-program Rechargeable Neurostimulator Implant Manual. Minneapolis, MN; 2008.
39. Goldsmith KA, Dyer MT, Schofield PM, Buxton MJ, Sharples LD. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes 2009;7(96):1-14.
40. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010;8(13):1-12.
41. Olsson GL, Meyerson BA, Linderoth B. Spinal cord stimulation in adolescents with complex regional pain syndrome type I (CRPS-I). Eur J Pain 2008;12(1):53-59.
42. Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: A review. Ann Vasc Surg 2008;22(2):297-306.
43. Klomp HM, Spincemaille GH, Steyerberg EW, Habbema JD, van Urk H. Efficacy of spinal cord stimulation in critical limb ischemia. Lancet 1999;353:1040-1044.
44. Klomp HM, Steyerberg EW, van Urk H, Habbema JD. Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia. Eur J Vasc Endovasc Surg 2006;31:500-508.
45. Ubbink DT, Vermeulen H, Spincemaille GH, etal. Systematic review and meta-analysis of controlled trials assessing spinal cord stimulation for inoperable critical leg ischaemia. Br J Surg 2004;91(8):948-955.
46. McNab D, Khan SN, Sharples LD, etal. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardi al laser revascularization in patients with refractory angina pectoris: The SPiRiT trial. Eur Heart J 2006;27:1048-1053.
47. Dyer MT, Goldsmith KA, Khan SN, etal. Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of Spinal Cord Stimulation versus Percutaneous Myocardial Laser Revascularisation in patients with Refractory Angina Pectoris: The SPiRiT trial. Trials 2008;9(40):1-11.
48. Levy RM. Spinal cord stimulation for medically refractory angina pectoris: Can the therapy be resuscitated? Neuromodulation 2011;14:1-5.
49. Andersen C, Hole P, Oxhoj H. Does pain relief with spinal cord stimulation for angina conceal myocardial infarction? Br Heart J 1994;71:419-421.
50. Andersen C. Does heart rate variability change in angina pectoris patients treated with spinal cord stimulation? Cardiology 1998;89:14-18.
51. Hollingworth W, Turner JA, Welton NJ, Comstock BA, Deyo RA. Costs and cost-effectiveness of spinal cord stimulation (SCS) for failed back surgery syndrome: An observational study in a workers' compensation population. Spine (Phila Pa 1976) 2011;36:2076-2083.
52. Rasmussen MB, Hole P, Andersen C. Electrical spinal cord stimulation (SCS) in the treatment of angina: A cost-utility analysis. Neuromodulation 2004;7:89-96.